Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.14 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance without providing specific guidance. They emphasized ongoing strategic efforts.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on strategic initiatives despite the current financial performance.
Celcuity Inc's earnings report showed a loss per share of $0.14, but no revenue figures were disclosed. The stock reacted negatively, dropping 5.48%, likely due to the lack of concrete financial data and guidance. Investors may be concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CRINETICS PHARMACEUT
Mar 9, 2020